Outset Medical, Inc. (OM) FY2025 10-K Annual Report
Outset Medical, Inc. (OM) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 13, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Outset Medical, Inc. FY2025 10-K Analysis
Business Overview
- • Core business model not detailed; focus on corporate governance and compliance policies
- • No new products, services, or segments introduced or emphasized this year
Management Discussion & Analysis
- • Revenue $119.5M, up 5% YoY from $113.7M; product revenue $84.8M (+5%), service revenue $34.7M (+6%)
- • Gross margin 39.1% vs 33.9%, gross profit $46.8M, up 21%, driven by higher console and consumable margins
Risk Factors
- • FDA warning letter in 2023 and ongoing compliance risks with medical device regulations impacting Tablo production and approval processes
- • Dependence on Mexico manufacturing exposed to U.S. tariffs risk from Section 232 Trade Expansion Act investigation started September 2025
Outset Medical, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$119M
▲ +5.1% YoY
Net Income
-$82M
▲ +36.2% YoY
Gross Margin
39.1%
▲ +521bp YoY
Operating Margin
-55.8%
▲ +4389bp YoY
Net Margin
-68.3%
▲ +4422bp YoY
ROE
-64.3%
▲ +41287bp YoY
Total Assets
$264M
▼ -4.1% YoY
EPS (Diluted)
$-5.37
▼ -118.3% YoY
Operating Cash Flow
-$46M
▲ +60.2% YoY
Source: XBRL data from Outset Medical, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Outset Medical, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.